CliffBio
small molecule

KOVANAZE

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyST RENATUS LLC

Drug detail

Brand nameKOVANAZE
Active ingredientOXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE
Strength0.1MG/SPRAY;6MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusRX

Listed patents

PatentExpiresType
9308191April 2030product
8580282April 2030product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KOVANAZE patent cliff — loss of exclusivity April 2030 | CliffBio